EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Eosinophils protect pressure overload- and β-adrenoreceptor agonist-induced cardiac hypertrophy

Chongzhe Yang, Jie Li, Zhiyong Deng, Songyuan Luo iD, Jing Liu iD, Wenqian Fang iD, Feng Liu, Tianxiao Liu iD, Xian Zhang iD, Yuanyuan Zhang, Zhaojie Meng, Shuya Zhang und 11 weitere

Cardiovascular Research · 2023

DOI: 10.1093/cvr/cvac060 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiovascular Research, 2023. Verfasst von Chongzhe Yang und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Geriatrics, National Key Clinical Specialty, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou 510000, China. Hauptthemen laut MEDLINE: Hypertrophy, Left Ventricular, Eosinophils. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, China International Medical Foundation, Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Blood eosinophil (EOS) counts and EOS cationic protein (ECP) levels associate positively with major cardiovascular disease (CVD) risk factors and prevalence. This study investigates the role of EOS in cardiac hypertrophy. Methods and results A retrospective cross-section study of 644 consecutive inpatients with hypertension examined the association between blood EOS counts and cardiac hypertrophy. Pressure overload- and β-adrenoreceptor agonist isoproterenol-induced cardiac hypertrophy was produced in EOS-deficient ΔdblGATA mice. This study revealed positive correlations between blood EOS counts and left ventricular (LV) mass and mass index in humans. ΔdblGATA mice showed exacerbated cardiac hypertrophy and dysfunction, with increased LV wall thickness, reduced LV internal diameter, and increased myocardial cell size, death, and fibrosis. Repopulation of EOS from wild-type (WT) mice, but not those from IL4-deficient mice ameliorated cardiac hypertrophy and cardiac dysfunctions. In ΔdblGATA and WT mice, administration of ECP mEar1 improved cardiac hypertrophy and function. Mechanistic studies demonstrated that EOS expression of IL4, IL13, and mEar1 was essential to control mouse cardiomyocyte hypertrophy and death and cardiac fibroblast TGF-β signalling and fibrotic protein synthesis. The use of human cardiac cells yielded the same results. Human ECP, EOS-derived neurotoxin, human EOS, or murine recombinant mEar1 reduced human cardiomyocyte death and hypertrophy and human cardiac fibroblast TGF-β signalling.

Conclusion

Although blood EOS counts correlated positively with LV mass or LV mass index in humans, this study established a cardioprotective role for EOS IL4 and cationic proteins in cardiac hypertrophy and tested a therapeutic possibility of ECPs in this human CVD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypertrophy, Left VentricularEosinophilsMiceHumansAnimalsRetrospective StudiesInterleukin-4CardiomegalyMyocytes, CardiacAdrenergic beta-AgonistsTransforming Growth Factor betaFibrosisVentricular Remodeling

Stichwörter der Autor:innen

Cardiac fibroblastCardiac hypertrophyCardiomyocyteEosinophilEosinophil cationic proteinInterleukin-4

Substanzen

Interleukin-4Adrenergic beta-AgonistsTransforming Growth Factor beta

Autor:innen und Institutionen

  • Department of Geriatrics, National Key Clinical Specialty, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou 510000, China.
  • Department of Medicine, Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, 77 Avenue Louis Pasteur, NRB-7, Boston, MA 02115, USA.
  • Department of Cardiology, Vascular Center, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangzhou 510000, China.
  • Hainan Provincial Key Laboratory for Tropical Cardiovascular Diseases Research & Key Laboratory of Emergency and Trauma of Ministry of Education, Institute of Cardiovascular Research of the First Affiliated Hospital, Ha…
  • Department of Biochemistry and Cancer Biology, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43614, USA.
  • Department of Chemistry, Bridge Institute, USC Michelson Center for Convergent Biosciences, University of Southern California, Los Angeles, CA 90089, USA.

ORCID-Profile: Songyuan Luo, Jing Liu, Wenqian Fang, Tianxiao Liu, Xian Zhang, Junli Guo, Guo-Ping Shi

Förderung

  • National Natural Science Foundation of China
  • China International Medical Foundation
  • Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences
  • Key Laboratory of Emergency and Trauma of Ministry of Education Hainan Medical University
  • Guangzhou Planed Project of Science and Technology
  • National Heart, Lung, and Blood Institute
  • National Institute of Neurological Disorders and Stroke

Zitieren

APA

Yang, C., Li, J., Deng, Z., Luo, S., Liu, J., Fang, W., Liu, F., Liu, T., Zhang, X., Zhang, Y., Meng, Z., Zhang, S., Luo, J., Liu, C., Yang, D., Liu, L., Sukhova, G. K., Sadybekov, A., Katritch, V., …, & Shi, G. P. (2023). Eosinophils protect pressure overload- and β-adrenoreceptor agonist-induced cardiac hypertrophy. Cardiovascular Research. https://doi.org/10.1093/cvr/cvac060

Vancouver

Yang C, Li J, Deng Z, Luo S, Liu J, Fang W, et al. Eosinophils protect pressure overload- and β-adrenoreceptor agonist-induced cardiac hypertrophy. Cardiovascular Research. 2023. doi:10.1093/cvr/cvac060

BibTeX
@article{Yang2023,
  author = {Yang, Chongzhe and Li, Jie and Deng, Zhiyong and Luo, Songyuan and Liu, Jing and Fang, Wenqian and Liu, Feng and Liu, Tianxiao and Zhang, Xian and Zhang, Yuanyuan and Meng, Zhaojie and Zhang, Shuya and Luo, Jianfang and Liu, Conglin and Yang, Dafeng and Liu, Lijun and Sukhova, Galina K and Sadybekov, Anastasiia and Katritch, Vsevolod and Libby, Peter and Wang, Jing and Guo, Junli and Shi, Guo-Ping},
  title = {Eosinophils protect pressure overload- and β-adrenoreceptor agonist-induced cardiac hypertrophy},
  journal = {Cardiovascular Research},
  year = {2023},
  doi = {10.1093/cvr/cvac060}
}
Kostenlos starten →